Related Experiment Video
Updated: Jul 8, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
[An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)"]
Abstract:
In order to provide the "guiding principles of clinical research on mild cognitive impairment (MCI) (protocol)" edited by Beijing United Study Group on MCI of the Capital Foundation of Medical Developments (CFMD) with evidence support, clinical criteria, subtypes, inclusion and exclusion of MCI, and use of rating scales were reviewed. The authors suggested that MCI clinical criteria and new diagnosis procedure from the MCI Working Group of the European Alzheimer's disease Consortium (EADC) may better reflect the heterogeneity of MCI syndrome. Diagnostic rating scales including Clinical Dementia Rating (CDR), Global Deterioration Scale (GDS), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Instrumental Activities of Daily Living (IADL) are very useful in definition of MCI but can not replace its clinical criteria. Absence of major repercussions on daily life in patients with MCI was emphasized, but the patients may have minimal impairment in complex IADL. According to their previous research, the authors concluded that highly recommendable neuropsychological scales with cut-off scores in the screening of MCI cases should include Mini-Mental State Examination (MMSE), logistic memory test such as Delayed Story Recall (DSR), executive function test such as Clock Draw Test (CDT), language test such as Verbal Category Fluency Test (VCFT), etc. And finally, the detection of biological and neuroimaging changes, including atrophy in hippocampus or medial temporal lobe in patients with MCI, was introduced.
Insights
Mild cognitive impairment (MCI) research requires refined diagnostic criteria and validated neuropsychological scales. This review supports evidence-based guidelines for MCI diagnosis, incorporating clinical assessments and biological markers.
Area of Science:
- Neurology
- Geriatrics
Background:
- Review of clinical criteria, subtypes, and diagnostic procedures for Mild Cognitive Impairment (MCI).
- Evaluation of existing rating scales (CDR, GDS, ADAS-cog, IADL) for MCI definition and their limitations.
- Emphasis on minimal impact on daily activities, with potential for subtle impairment in complex Instrumental Activities of Daily Living (IADL).
Discussion:
- Comparison of Beijing United Study Group's principles with the European Alzheimer's Disease Consortium (EADC) criteria for MCI diagnosis.
- Highlighting the EADC criteria's potential to better capture MCI syndrome heterogeneity.
- Discussion on the role of diagnostic scales versus clinical criteria in MCI assessment.
Key Insights:
- Neuropsychological scales like Mini-Mental State Examination (MMSE), Delayed Story Recall (DSR), Clock Draw Test (CDT), and Verbal Category Fluency Test (VCFT) are recommended for MCI screening with established cut-off scores.
- Biological and neuroimaging markers, such as medial temporal lobe and hippocampal atrophy, are crucial for MCI detection.
- Absence of major daily life repercussions is characteristic of MCI, though minimal impairment in complex IADL may be present.
Outlook:
- Future research should focus on integrating clinical, neuropsychological, and biomarker data for robust MCI diagnosis.
- Development of standardized protocols for MCI research based on evidence-based principles.
- Continued refinement of diagnostic criteria to address the heterogeneity of MCI and its progression.
More Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Treatment
Ethics in Research
Dementia l: Introduction